{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T01:03:42Z","timestamp":1773363822571,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1053\/j.seminoncol.2004.02.020","type":"journal-article","created":{"date-parts":[[2005,11,3]],"date-time":"2005-11-03T13:58:14Z","timestamp":1131026294000},"page":"91-98","source":"Crossref","is-referenced-by-count":10,"special_numbering":"S4","title":["New options for the treatment of invasive fungal infections"],"prefix":"10.1053","volume":"31","author":[{"given":"Zachary A","family":"Rubin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyoti","family":"Somani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2004.02.020_BIB1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1128\/AAC.44.3.747-751.2000","article-title":"bloodstream infections due to Candida Species","volume":"44","author":"Pfaller","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1086\/342300","article-title":"secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989\u20131999","volume":"35","author":"Trick","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0732-8893(97)00240-X","article-title":"National surveillance of nosocomial blood stream infection due to candida albicans","volume":"31","author":"Pfaller","year":"1998","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB4","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0196-6553(99)70031-3","article-title":"National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999","volume":"27","year":"1999","journal-title":"Am J Infect Control"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB5","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0002-9343(96)80072-6","article-title":"Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis","volume":"101","author":"Anaissie","year":"1996","journal-title":"Am J Med"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB6","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1056\/NEJM199411173312001","article-title":"A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia","volume":"331","author":"Rex","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/jac\/dkf074","article-title":"In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients","volume":"50","author":"Laverdiere","year":"2002","journal-title":"J Antibiot Chemother"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/02681219780001291","article-title":"In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates","volume":"35","author":"Nelson","year":"1997","journal-title":"J Med Vet Mycol"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB9","series-title":"In vitro activity of the echinocandin caspofungin (MK-0991) against refractory clinical isolates of candida and aspergillus species","author":"Sutton","year":"2001"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0732-8893(99)00046-2","article-title":"International surveillance of blood stream infections due to Candida species in the European SENTRY Program","volume":"35","author":"Pfaller","year":"1999","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB11","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1128\/JCM.36.10.2950-2956.1998","article-title":"Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts","volume":"36","author":"Espinel-Ingroff","year":"1998","journal-title":"J Clin Microbiol"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB12","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB13","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/339202","article-title":"Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients","volume":"34","author":"Marr","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1086\/323335","article-title":"Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants","volume":"34","author":"Ascioglu","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/1097-0142(20010115)91:2<311::AID-CNCR1003>3.0.CO;2-3","article-title":"Value of antigen detection using in enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study","volume":"91","author":"Sulahian","year":"2001","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB16","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood.V97.6.1604","article-title":"Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients","volume":"97","author":"Maertens","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB17","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/516343","article-title":"Comparison of serum galactomannan antigen detection and competitive polymerase chain reaction for diagnosing invasive aspergillosis","volume":"26","author":"Bretagne","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB18","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/clinids\/23.3.608","article-title":"Therapeutic outcomes of invasive aspergillosis","volume":"23","author":"Denning","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB19","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/318483","article-title":"Aspergillus case-fatality rate","volume":"32","author":"Lin","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB20","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/516353","article-title":"Amphotericin B lipid complex for invasive fungal infections","volume":"26","author":"Walsh","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0002-9343(94)90023-X","article-title":"Multicenter Trial of oral itraconazole therapy for invasive aspergillosis","volume":"97","author":"Denning","year":"1994","journal-title":"Am J Med"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB22","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1001\/archinte.157.16.1857","article-title":"Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria","volume":"157","author":"Stevens","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB23","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB24","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1086\/374252","article-title":"Voriconazole inhibition of tacrolimus metabolism","volume":"36","author":"Pai","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB25","series-title":"In vitro activity of the echinocandin caspofungin (MK-0991) against refractory clinical isolates of candida and aspergillus species","author":"Sutton","year":"2001"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB26","series-title":"In vitro susceptibility of clinical trial isolates of Aspergillus spp. to the echinocandin antifungal caspofungin","author":"Flattery","year":"2000"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB27","series-title":"Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin, amphotericin B, lipid formulations, or azoles","author":"Maertens","year":"2000"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB28","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/jac\/dkg242","article-title":"Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus","volume":"51","author":"Manavathu","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB29","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1128\/AAC.46.1.245-247.2002","article-title":"In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp","volume":"46","author":"Arikan","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB30","series-title":"In vitro additive and synergistic effect of two echinocandins, caspofungin and micafungin with voriconazole against Aspergillus fumigatus","author":"Oshaughnessy","year":"2002"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB31","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/cncr.11115","article-title":"Refractory Aspergillus Pneumonia in patients with acute leukemia","volume":"97","author":"Aliff","year":"2003","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB32","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1128\/AAC.46.10.3208-3214.2002","article-title":"Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis","volume":"46","author":"Lewis","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 3","key":"10.1053\/j.seminoncol.2004.02.020_BIB33","doi-asserted-by":"crossref","first-page":"S188","DOI":"10.1086\/376524","article-title":"Combination and sequential antifungal therapy for invasive aspergillosis","volume":"37","author":"Steinbach","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB34","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/339202","article-title":"Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients","volume":"34","author":"Marr","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB35","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1517\/13543784.11.3.409","article-title":"Review of the safety and efficacy of voriconazole","volume":"11","author":"Hoffman","year":"2002","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB36","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1128\/JCM.39.3.954-958.2001","article-title":"In vitro activities of voriconazole, itraconazole and amphotericin B against opportunistic moniliaceous and dematiaceous fungi","volume":"39","author":"Espinel-Ingroff","year":"2001","journal-title":"J Clin Microbiol"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB37","first-page":"573","article-title":"In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species","volume":"17","author":"Clancy","year":"1998","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB38","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1128\/AAC.46.4.1032-1037.2002","article-title":"Antifungal activities of posaconazole, ravuconazole and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi","volume":"46","author":"Pfaller","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jac\/dkg020","article-title":"In vitro susceptibilities of zygomycetes to conventional and new antifungals","volume":"51","author":"Dannaoui","year":"2003","journal-title":"J Antimicrobial Chemother"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB40","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1439-0507.1998.tb00344.x","article-title":"In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin","volume":"41","author":"Wildfeuer","year":"1998","journal-title":"Mycoses"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB41","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1128\/AAC.46.7.2310-2312.2002","article-title":"In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model","volume":"46","author":"Sun","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB42","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1128\/AAC.45.12.3487-3496.2001","article-title":"Safety, tolerance and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi","volume":"45","author":"Walsh","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/j.seminoncol.2004.02.020_BIB43","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1086\/368312","article-title":"Continuous infusion of escalated doses of Amphotericin B Deoxycholate","volume":"36","author":"Imhof","year":"2003","journal-title":"Clin Infect Dis"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009377540400079X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009377540400079X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T17:05:04Z","timestamp":1586538304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009377540400079X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":43,"alternative-id":["S009377540400079X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2004.02.020","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}